Analysts Set Zura Bio Limited (NASDAQ:ZURA) PT at $15.80

Shares of Zura Bio Limited (NASDAQ:ZURA) have earned a consensus rating of “Buy” from the seven analysts that are presently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a hold recommendation, five have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month price target among brokerages that have covered the stock in the last year is $15.80.

A number of brokerages have recently issued reports on ZURA. Leerink Partnrs raised shares of Zura Bio to a “strong-buy” rating in a research note on Monday, November 4th. Chardan Capital decreased their price objective on shares of Zura Bio from $14.00 to $12.00 and set a “buy” rating for the company in a report on Friday, November 8th. Cantor Fitzgerald restated an “overweight” rating on shares of Zura Bio in a research note on Wednesday, December 11th. Leerink Partners assumed coverage on shares of Zura Bio in a research note on Monday, November 4th. They set an “outperform” rating and a $15.00 price target for the company. Finally, Piper Sandler restated an “overweight” rating and set a $26.00 price objective on shares of Zura Bio in a report on Thursday, September 19th.

Insider Activity at Zura Bio

In related news, Director Parvinder Thiara sold 1,001,633 shares of the firm’s stock in a transaction dated Monday, November 25th. The stock was sold at an average price of $2.73, for a total transaction of $2,734,458.09. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. 22.10% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Zura Bio

Several institutional investors and hedge funds have recently bought and sold shares of the company. AQR Capital Management LLC purchased a new stake in shares of Zura Bio during the second quarter worth about $43,000. Healthcare of Ontario Pension Plan Trust Fund purchased a new stake in Zura Bio during the 3rd quarter worth approximately $46,000. Renaissance Technologies LLC increased its stake in Zura Bio by 51.3% during the 2nd quarter. Renaissance Technologies LLC now owns 17,400 shares of the company’s stock valued at $61,000 after purchasing an additional 5,900 shares in the last quarter. SG Americas Securities LLC purchased a new position in shares of Zura Bio in the third quarter worth $62,000. Finally, Valence8 US LP acquired a new stake in shares of Zura Bio during the third quarter worth $71,000. 61.14% of the stock is owned by hedge funds and other institutional investors.

Zura Bio Trading Down 6.4 %

Shares of NASDAQ:ZURA opened at $2.50 on Wednesday. Zura Bio has a 12 month low of $2.00 and a 12 month high of $6.35. The firm’s 50-day moving average is $3.38 and its 200 day moving average is $3.64.

Zura Bio (NASDAQ:ZURA) last released its earnings results on Thursday, November 7th. The company reported ($0.26) EPS for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.12). Sell-side analysts anticipate that Zura Bio will post -0.65 earnings per share for the current year.

About Zura Bio

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.